IRIDEX Corporation (IRIX)

US — Healthcare Sector
Peers: AZYO  AIMD  SRDX  LNSR  AMEUF  AIMDW  ARMM  CLLKF  BBLGW  NVNO  PETV  TLIS  TNON  SSKN  SIEN  AXGN  RXST  TMCI  LUNG  OFIX 

Automate Your Wheel Strategy on IRIX

With Tiblio's Option Bot, you can configure your own wheel strategy including IRIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IRIX
  • Rev/Share 2.9177
  • Book/Share 0.4096
  • PB 20.6143
  • Debt/Equity 1.9425
  • CurrentRatio 1.9488
  • ROIC -0.257

 

  • MktCap 17628450.0
  • FreeCF/Share -0.4061
  • PFCF -2.5955
  • PE -2.4626
  • Debt/Assets 0.0483
  • DivYield 0
  • ROE -2.9057

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Iridex Announces Strategic Investment in the Company
IRIX
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. (“Novel”), an investment company founded in 2020, which had the assistance of William Moore, …

Read More
image for news Iridex Announces Strategic Investment in the Company

About IRIDEX Corporation (IRIX)

  • IPO Date 1996-02-16
  • Website https://www.iridex.com
  • Industry Medical - Devices
  • CEO Mr. Patrick Mercer
  • Employees 93
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.